Health Costs

New and noteworthy

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Health System Tracker

Stay informed.

Stay informed.

Filter

441-450 of 1,609 results

  • Next Steps in Covering Uninsured Children: Findings from the Kaiser Survey of Children’s Health Coverage

    Issue Brief

    This issue brief provides key findings from the Kaiser Survey of Children's Health Coverage, including that many low- and middle-income working families with an uninsured child do not have access to employer-sponsored health insurance. The telephone survey of parents that was conducted in 2007 to learn more about children’s access to coverage and care and the health care cost-related pressures facing their families. Issue Brief (.pdf)

  • Pulling It Together: What Conservatives Won In Health Reform (And Don’t Seem to Know It)

    Perspective

    Conservatives obviously don't like what they call "Obamacare" because they think it expands the role of government too much and spends too much money.  But ironically, the Affordable Care Act (ACA) actually promotes -- though not explicitly -- something that has been a fundamental objective of conservatives in health care for years: high-deductible health plans with more "skin in the game." In a new study we just released, we commissioned three different actuarial consulting firms…

  • Characteristics of Frequent Emergency Department Users

    Report

    The increased use of U.S. hospital emergency departments has received considerable attention from both the health care community and policymakers in recent years. This analysis from the Kaiser Family Foundation examines the demographic and health characteristics of people who frequently visit the emergency room to help understand why their utilization is so high. Using data from the nationally representative Medical Expenditures Panel Survey, the analysis finds that high emergency department users (those who made four…

  • The Role of PBMs in Managing Drug Costs: Implications for a Medicare Drug Benefit

    Other Post

    Extending a drug benefit to Medicare beneficiaries has been a highly publicized issue in recent months. To address the question of how to finance and administer such a benefit while controlling its cost, some have proposed using pharmacy benefit managers (PBMs)--companies that administer pharmaceutical benefits for health plans, HMOs, and employers while managing drug utilization and obtaining discounts from both retail pharmacies and manufacturers. Most recently, the Clinton Administration introduced a proposal for a Medicare…

  • Medicaid and HIV/AIDS Policy: A Basic Primer

    Report

    The Medicaid Primer presents in depth information on Medicaid, the federal/state program that provides health coverage for low-income families and people with disabilities and is the largest source of public financing for HIV/AIDS care in the U.S. The Medicaid Primer is designed to help policymakers and advocates navigate through the complexities of Medicaid with regard to the program's role for people with HIV/AIDS. REPORT Download

  • FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

    Issue Brief

    The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen's new FDA-approved Alzheimer's drug, which will cost $56,000 per year.

  • Early Results from Federal Price Transparency Rule Show Difficultly in Estimating the Cost of Care

    Issue Brief

    A new issue brief examines compliance with a new federal price transparency rule and variation in payer-negotiated rates at U.S. hospitals. The analysis looks at the websites of the two largest hospitals in each state and the District of Columbia, and finds that a lack of consistency in the data and limited compliance among the hospitals sampled makes it difficult to compare prices across facilities. The brief is available on the Peterson-KFF Health System Tracker,…

  • ACA’s Maximum Out-of-Pocket Limit Is Growing Faster Than Wages

    Issue Brief

    This analysis finds that the ACA’s maximum out-of-pocket limit is likely to grow faster than wages and salaries, and is also expected to grow faster than the maximum out-of-pocket limit for Health Savings Account (HSA)-qualified health plans.

  • USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies

    Poll Finding

    This poll, the third in a series conducted jointly by USA Today and public opinion researchers at the Kaiser Family Foundation and the Harvard School of Public Health, by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health finds Americans greatly value prescription drugs’ potential benefits for their families, but most believe they cost too much money and many struggle to pay for needed medicines. The survey also provides a comprehensive…